查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1225045

患者血液管理市場：按產品、按成分、按最終用戶：全球機會分析和行業預測，2021-2031 年

Patient Blood Management Market By Product, By Component, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 | 商品交期: 2-3個工作天內

價格

患者血液管理是一種基於證據的多學科方法，用於護理可能需要輸血的患者。

它涵蓋輸血決策過程的所有方面，從最初的患者評估到臨床管理。 這些技術旨在確保最佳的患者治療效果，同時維持血液供應以在需要時向患者提供血液成分。

患者血液管理通過增加和保存患者自身的血液來改善患者的醫療和手術管理，從而改善患者的預後。 改進的患者血液管理通常允許患者較少地輸注捐獻的血液成分並避免與輸血相關的併發症。 澳大利亞國家血液局資助並管理基於證據的患者血液管理指南的製定。

推動患者血液管理市場增長的關鍵因素包括患者血液管理設備的技術進步、全球人口中血液病患病率的上升以及獻血者數量的激增。 此外，血癌患病率上升、瘧疾和癌症等疾病患病率上升也推動了這一市場的增長。 例如，根據白血病和淋巴瘤協會的數據，美國白血病、淋巴瘤和骨髓瘤的新病例將佔 2021 年估計的 1,898,160 例新癌症病例的 9.8%，增加了對患者血液管理的需求。

但是，用於患者血液管理的設備和裝置的高成本以及不利的醫療費用預計會阻礙市場增長。 同時，新興國家未滿足的醫療需求和有利可圖的商機有望在未來為全球患者血液管理設備製造商帶來巨大機遇。

此外，慢性病的增加和外科手術的增加預計將促進醫療保健業務的發展，這將促進患者血液管理市場的增長。 此外，導致失血的交通事故增加、獻血意識提高以及政府在醫療保健方面的支出增加推動了患者血液管理市場的增長。 因此，預計主要參與者在預測期內對市場的投資將帶來有利可圖的機會。

內容

第 1 章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 上層投資口袋
  • 波特的五力分析
    • 供應商議價能力強
    • 買家議價能力強
    • 替代品的威脅很大
    • 新進入者的威脅很大
    • 競爭激烈程度
  • 市場動態
    • 促進因素
      • 受傷和事故發生率增加
      • 血癌增加
      • 增加政府在醫療保健方面的支出
    • 抑制因素
      • 與輸血程序相關的風險
      • 先進的患者血液管理產品成本高
    • 機會
      • 全球對血液和血液相關產品的需求增加
      • 全球獻血和血漿捐贈激增
  • 分析 COVID-19 對市場的影響

第 4 章患者血液管理市場：按產品分類

  • 概覽
    • 市場規模和預測
  • 按產品分類
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
    • 儀器化患者血液管理市場，按類型
      • 血液處理設備市場規模和預測：按地區
      • 輸血設備的市場規模和預測：按地區
      • 血細胞培養檢測設備市場規模和預測：按地區
      • 診斷/測試設備市場規模趨勢和預測：按地區
      • 血液儲存設備的市場規模和預測：按地區
  • 配飾
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
    • 輔助患者血液管理市場，按類型
      • 注射器和針頭市場規模和預測：按地區
      • 小瓶和試管市場規模趨勢和預測：按地區
      • 血袋市場規模和預測：按地區
      • 其他市場規模和預測：按地區
  • 試劑和試劑盒
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
    • 試劑和試劑盒患者血液管理市場：按類型分類
      • 血液培養基市場規模和預測：按地區
      • 血型檢測試劑的市場規模和預測：按地區
      • 載玻片染色試劑的市場規模和預測：按地區
      • 檢測試劑盒市場規模和預測：按地區
  • 軟件
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 5 章患者血液管理市場：按組成部分

  • 概覽
    • 市場規模和預測
  • 全血和紅細胞
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 等離子
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 6 章患者血液管理市場：按最終用戶分類

  • 概覽
    • 市場規模和預測
  • 血庫
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 醫院
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 診斷診所和病理實驗室
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 7 章患者血液管理市場：按地區

  • 概覽
    • 市場規模/預測：按地區
  • 北美
    • 主要趨勢和機會
    • 市場規模/預測：按產品
      • 北美儀器和患者血液管理市場：按類型分類
      • 北美患者血液管理配件市場，按類型
      • 北美患者血液管理試劑和試劑盒市場：按類型分類
    • 市場規模和預測：按組件
    • 市場規模和預測：按最終用戶分類
    • 市場規模/預測：按國家/地區分類
      • 美國
      • 主要市場趨勢、增長因素和機遇
      • 市場規模/預測：按產品
      • 市場規模和預測：按組件
      • 市場規模和預測：按最終用戶分類
      • 加拿大
      • 主要市場趨勢、增長因素和機遇
      • 市場規模/預測：按產品
      • 市場規模和預測：按組件
      • 市場規模和預測：按最終用戶分類
      • 墨西哥
      • 主要市場趨勢、增長因素和機遇
      • 市場規模/預測：按產品
      • 市場規模和預測：按組件
      • 市場規模和預測：按最終用戶分類
  • 歐洲
    • 主要趨勢和機會
    • 市場規模/預測：按產品
      • 歐洲儀器和患者血液管理市場：按類型分類
      • 歐洲患者血液管理配件市場：按類型分類
      • 歐洲試劑和試劑盒患者血液管理市場：按類型分類
    • 市場規模和預測：按組件
    • 市場規模和預測：按最終用戶分類
    • 市場規模/預測：按國家/地區分類
      • 德國
      • 主要市場趨勢、增長因素和機遇
      • 市場規模/預測：按產品
      • 市場規模和預測：按組件
      • 市場規模和預測：按最終用戶分類
      • 法國
      • 主要市場趨勢、增長因素和機遇
      • 市場規模/預測：按產品
      • 市場規模和預測：按組件
      • 市場規模和預測：按最終用戶分類
      • 英國
      • 主要市場趨勢、增長因素和機遇
      • 市場規模/預測：按產品
      • 市場規模和預測：按組件
      • 市場規模和預測：按最終用戶分類
      • 意大利
      • 主要市場趨勢、增長因素和機遇
      • 市場規模/預測：按產品
      • 市場規模和預測：按組件
      • 市場規模和預測：按最終用戶分類
      • 西班牙
      • 主要市場趨勢、增長因素和機遇
      • 市場規模/預測：按產品
      • 市場規模和預測：按組件
      • 市場規模和預測：按最終用戶分類
      • 其他歐洲
      • 主要市場趨勢、增長因素和機遇
      • 市場規模/預測：按產品
      • 市場規模和預測：按組件
      • 市場規模和預測：按最終用戶分類
  • 亞太地區
    • 主要趨勢和機會
    • 亞太市場規模和預測：按產品
      • 亞太地區患者血液管理設備市場，按類型
      • 亞太地區患者血液管理配件市場，按類型
      • 亞太地區患者血液管理試劑和試劑盒市場：按類型分類
    • 亞太地區患者血液管理市場規模和預測：按組成部分
    • 亞太地區患者血液管理市場規模和預測：按最終用戶分類
    • 亞太地區患者血液管理市場規模和預測：按國家/地區分類
      • 中國
      • 主要市場趨勢、增長因素和機遇
      • 市場規模/預測：按產品
      • 市場規模和預測：按組件
      • 市場規模和預測：按最終用戶分類
      • 日本
      • 主要市場趨勢、增長因素和機遇
      • 市場規模/預測：按產品
      • 市場規模和預測：按組件
      • 市場規模和預測：按最終用戶分類
      • 印度
      • 主要市場趨勢、增長因素和機遇
      • 市場規模/預測：按產品
      • 市場規模和預測：按組件
      • 市場規模和預測：按最終用戶分類
      • 澳大利亞
      • 主要市場趨勢、增長因素和機遇
      • 市場規模/預測：按產品
      • 市場規模和預測：按組件
      • 市場規模和預測：按最終用戶分類
      • 其他亞太地區
      • 主要市場趨勢、增長因素和機遇
      • 市場規模/預測：按產品
      • 市場規模和預測：按組件
      • 市場規模和預測：按最終用戶分類
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機會
    • 市場規模/預測：按產品
      • LAMEA 儀器和患者血液管理市場：按類型分類
      • LAMEA 患者血液管理配件市場，按類型
      • LAMEA 患者血液管理試劑和試劑盒市場：按類型分類
    • 市場規模和預測：按組件
    • 市場規模和預測：按最終用戶分類
    • 市場規模/預測：按國家/地區分類
      • 巴西
      • 主要市場趨勢、增長因素和機遇
      • 市場規模/預測：按產品
      • 市場規模和預測：按組件
      • 市場規模和預測：按最終用戶分類
      • 沙特阿拉伯
      • 主要市場趨勢、增長因素和機遇
      • 市場規模/預測：按產品
      • 市場規模和預測：按組件
      • 市場規模和預測：按最終用戶分類
      • 南非
      • 主要市場趨勢、增長因素和機遇
      • 市場規模/預測：按產品
      • 市場規模和預測：按組件
      • 市場規模和預測：按最終用戶分類
      • 拉美其他地區
      • 主要市場趨勢、增長因素和機遇
      • 市場規模/預測：按產品
      • 市場規模和預測：按組件
      • 市場規模和預測：按最終用戶分類

第 8 章競爭格局

  • 介紹
  • 關鍵成功策略
  • 排名前 10 位的玩家產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 定位頂級公司，2021 年

第 9 章公司簡介

  • Asahi Kasei Corporation
  • B. Braun SE
  • Biomerieux SA
  • Grifols, S.A.
  • Haemonetics Corporation
  • Haier Biomedical
  • Immucor, Inc
  • LivaNova PLC
  • Macopharma
  • Terumo Corporation
Product Code: A11262

Patient blood management is an evidence-based and multidisciplinary approach to caring for patients who might need a blood transfusion. It encompasses all aspects of the transfusion decision-making process, beginning with the initial patient evaluation and continuing through clinical management. These techniques are designed to ensure optimal patient outcomes while maintaining the blood supply to guarantee that blood components are available for patients when they are needed. 

Patient Blood Management improves patient outcomes by improving the patient's medical and surgical management in ways that boost and conserve the patient's own blood. Owing to better management, patients usually require fewer transfusions of donated blood components, thus avoiding transfusion-associated complications. The National Blood Authority of Australia is funding and managing the development of evidence-based patient blood management guidelines.

Major factors driving the growth of the patient blood management market include a rise in technological advancement in patient blood management devices, an increase in the prevalence of blood disorders among the global population, and a surge in the number of blood donors. Furthermore, the rise in the prevalence rate of blood cancer and the increase in the prevalence of diseases such as malaria and cancer enhance the growth of this market. For instance, according to the data from Leukemia & Lymphoma Society, in 2021, new cases of leukemia, lymphoma, and myeloma accounted for 9.8% of the estimated 1,898,160 new cancer cases in the U.S. This led to an increase in the requirement of patient blood management. 

However, unfavorable reimbursements as well as high costs of instruments and devices that are used in patient blood management are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for patient blood management device manufacturers worldwide in the future.

Furthermore, the healthcare business is projected to witness growth owing to a rise in chronic diseases and an increase in the number of surgical procedures performed, boosting the growth of the patient blood management market. Moreover, the increase in road accidents that cause blood loss, the rise in awareness regarding blood donation, and the increase in government expenditure on healthcare drive the growth of the patient blood management market. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.

In addition, rise in R&D investments in the discovery & development of safe and effective patient blood management devices, a significant rise in capital income in developed countries, and a rise in key strategies such as product launch, collaboration, merger, & acquisition adopted by key players strengthen demand for patient blood management devices in the market. 

For instance, in July 2019, Grifols, a global healthcare company, and producer of plasma-derived medicines announced the acquisition of its first donation center in Canada as part of the company's commitment to increase the availability of lifesaving plasma medicines in the country. In a share purchase agreement, Grifols Canada Therapeutics Inc has acquired Prometic Plasma Resources Inc's (PPR) donation center in Winnipeg from Kedrion for USD 4 million in cash. It is designed such that it can screen blood and plasma more efficiently within a smaller space than commercially available competitive systems. In a testing specialty that needs extensive hands-on time, the additional automation and flexibility of Alinity's are expected to help blood and plasma centers improve productivity and maintain the highest levels of accuracy. Hence, such factors drive the growth of the patient blood management market.

The patient blood management market is segmented on the basis of product, component, end user, and region. On the basis of product, the market is classified into instruments (blood processing devices, blood transfusion devices, blood culture screening devices, diagnostic & testing instruments, and blood storage devices), accessories (syringes & needles, vials & tubes, blood bags, and others), reagents & kits (blood culture media, blood typing reagents, slide staining reagents, and assay kits), and software. On the basis of components, the market is classified into whole blood & red blood cells, and plasma. Depending on the end user, it is fragmented into hospitals, blood banks, and diagnostic clinics & pathology labs. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). 

Major players profiled in the report are Asahi Kasei Corporation, B. Braun SE, BioMerieux, Inc., Grifols, S.A., Haemonetics Corporation, Haier Biomedical, Immucor, Inc., LivaNova PLC, Macopharma, and Terumo Corporation.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the patient blood management market analysis from 2021 to 2031 to identify the prevailing patient blood management market opportunities.

Market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the patient blood management market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global patient blood management market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Component

  • Whole Blood and Red Blood Cells
  • Plasma

By End User

  • Blood Banks
  • Hospitals
  • Diagnostic Clinics and Pathology Labs

By Product

  • Instruments
    • Type
    • Blood Processing Devices
    • Blood Transfusion Devices
    • Blood Culture Screening Devices
    • Diagnostic and Testing Instruments
    • Blood Storage Devices
  • Accessories
    • Type
    • Syringes and Needles
    • Vials and Tubes
    • Blood Bags
    • Others
  • Reagents and Kits
    • Type
    • Blood Culture Media
    • Blood Typing Reagents
    • Slide Staining Reagents
    • Assay Kits
  • Software

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Grifols, S.A.
    • B. Braun SE
    • Immucor, Inc
    • Haemonetics Corporation
    • LivaNova PLC
    • Biomerieux SA
    • Haier Biomedical
    • Macopharma
    • Terumo Corporation
    • Asahi Kasei Corporation

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. High bargaining power of suppliers
    • 3.3.2. High bargaining power of buyers
    • 3.3.3. High threat of substitutes
    • 3.3.4. High threat of new entrants
    • 3.3.5. High intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in incidence of trauma and accidents
      • 3.4.1.2. Increase in prevalence of blood cancer
      • 3.4.1.3. Increase in government expenditure on healthcare
    • 3.4.2. Restraints
      • 3.4.2.1. Risks related to blood transfusion procedure
      • 3.4.2.2. High cost of advanced patient blood management products
    • 3.4.3. Opportunities
      • 3.4.3.1. Rise in demand for blood and other blood related products across the globe
      • 3.4.3.2. Surge in blood donations and plasma donations across the globe
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Instruments
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
    • 4.2.4. Instruments Patient Blood Management Market by Type
      • 4.2.4.1. Blood Processing Devices Market size and forecast, by region
      • 4.2.4.2. Blood Transfusion Devices Market size and forecast, by region
      • 4.2.4.3. Blood Culture Screening Devices Market size and forecast, by region
      • 4.2.4.4. Diagnostic and Testing Instruments Market size and forecast, by region
      • 4.2.4.5. Blood Storage Devices Market size and forecast, by region
  • 4.3. Accessories
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
    • 4.3.4. Accessories Patient Blood Management Market by Type
      • 4.3.4.1. Syringes and Needles Market size and forecast, by region
      • 4.3.4.2. Vials and Tubes Market size and forecast, by region
      • 4.3.4.3. Blood Bags Market size and forecast, by region
      • 4.3.4.4. Others Market size and forecast, by region
  • 4.4. Reagents and Kits
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
    • 4.4.4. Reagents and Kits Patient Blood Management Market by Type
      • 4.4.4.1. Blood Culture Media Market size and forecast, by region
      • 4.4.4.2. Blood Typing Reagents Market size and forecast, by region
      • 4.4.4.3. Slide Staining Reagents Market size and forecast, by region
      • 4.4.4.4. Assay Kits Market size and forecast, by region
  • 4.5. Software
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Whole Blood and Red Blood Cells
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Plasma
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: PATIENT BLOOD MANAGEMENT MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Blood Banks
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Hospitals
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Diagnostic Clinics and Pathology Labs
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: PATIENT BLOOD MANAGEMENT MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Product
      • 7.2.2.1. North America Instruments Patient Blood Management Market by Type
      • 7.2.2.2. North America Accessories Patient Blood Management Market by Type
      • 7.2.2.3. North America Reagents and Kits Patient Blood Management Market by Type
    • 7.2.3. Market size and forecast, by Component
    • 7.2.4. Market size and forecast, by End User
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Product
      • 7.2.5.1.3. Market size and forecast, by Component
      • 7.2.5.1.4. Market size and forecast, by End User
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Product
      • 7.2.5.2.3. Market size and forecast, by Component
      • 7.2.5.2.4. Market size and forecast, by End User
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Product
      • 7.2.5.3.3. Market size and forecast, by Component
      • 7.2.5.3.4. Market size and forecast, by End User
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Product
      • 7.3.2.1. Europe Instruments Patient Blood Management Market by Type
      • 7.3.2.2. Europe Accessories Patient Blood Management Market by Type
      • 7.3.2.3. Europe Reagents and Kits Patient Blood Management Market by Type
    • 7.3.3. Market size and forecast, by Component
    • 7.3.4. Market size and forecast, by End User
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Product
      • 7.3.5.1.3. Market size and forecast, by Component
      • 7.3.5.1.4. Market size and forecast, by End User
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Product
      • 7.3.5.2.3. Market size and forecast, by Component
      • 7.3.5.2.4. Market size and forecast, by End User
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Product
      • 7.3.5.3.3. Market size and forecast, by Component
      • 7.3.5.3.4. Market size and forecast, by End User
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Product
      • 7.3.5.4.3. Market size and forecast, by Component
      • 7.3.5.4.4. Market size and forecast, by End User
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Product
      • 7.3.5.5.3. Market size and forecast, by Component
      • 7.3.5.5.4. Market size and forecast, by End User
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Product
      • 7.3.5.6.3. Market size and forecast, by Component
      • 7.3.5.6.4. Market size and forecast, by End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Product
      • 7.4.2.1. Asia-Pacific Instruments Patient Blood Management Market by Type
      • 7.4.2.2. Asia-Pacific Accessories Patient Blood Management Market by Type
      • 7.4.2.3. Asia-Pacific Reagents and Kits Patient Blood Management Market by Type
    • 7.4.3. Market size and forecast, by Component
    • 7.4.4. Market size and forecast, by End User
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. China
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Product
      • 7.4.5.1.3. Market size and forecast, by Component
      • 7.4.5.1.4. Market size and forecast, by End User
      • 7.4.5.2. Japan
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Product
      • 7.4.5.2.3. Market size and forecast, by Component
      • 7.4.5.2.4. Market size and forecast, by End User
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Product
      • 7.4.5.3.3. Market size and forecast, by Component
      • 7.4.5.3.4. Market size and forecast, by End User
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Product
      • 7.4.5.4.3. Market size and forecast, by Component
      • 7.4.5.4.4. Market size and forecast, by End User
      • 7.4.5.5. Rest of Asia-Pacific
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Product
      • 7.4.5.5.3. Market size and forecast, by Component
      • 7.4.5.5.4. Market size and forecast, by End User
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Product
      • 7.5.2.1. LAMEA Instruments Patient Blood Management Market by Type
      • 7.5.2.2. LAMEA Accessories Patient Blood Management Market by Type
      • 7.5.2.3. LAMEA Reagents and Kits Patient Blood Management Market by Type
    • 7.5.3. Market size and forecast, by Component
    • 7.5.4. Market size and forecast, by End User
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Product
      • 7.5.5.1.3. Market size and forecast, by Component
      • 7.5.5.1.4. Market size and forecast, by End User
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Product
      • 7.5.5.2.3. Market size and forecast, by Component
      • 7.5.5.2.4. Market size and forecast, by End User
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Product
      • 7.5.5.3.3. Market size and forecast, by Component
      • 7.5.5.3.4. Market size and forecast, by End User
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Product
      • 7.5.5.4.3. Market size and forecast, by Component
      • 7.5.5.4.4. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Asahi Kasei Corporation
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. B. Braun SE
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Biomerieux SA
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Grifols, S.A.
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Haemonetics Corporation
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Haier Biomedical
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
  • 9.7. Immucor, Inc
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
  • 9.8. LivaNova PLC
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Macopharma
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
  • 9.10. Terumo Corporation
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 02. PATIENT BLOOD MANAGEMENT MARKET FOR INSTRUMENTS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 03. GLOBAL INSTRUMENTS PATIENT BLOOD MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 04. PATIENT BLOOD MANAGEMENT MARKET FOR BLOOD PROCESSING DEVICES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 05. PATIENT BLOOD MANAGEMENT MARKET FOR BLOOD TRANSFUSION DEVICES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 06. PATIENT BLOOD MANAGEMENT MARKET FOR BLOOD CULTURE SCREENING DEVICES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 07. PATIENT BLOOD MANAGEMENT MARKET FOR DIAGNOSTIC AND TESTING INSTRUMENTS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 08. PATIENT BLOOD MANAGEMENT MARKET FOR BLOOD STORAGE DEVICES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 09. PATIENT BLOOD MANAGEMENT MARKET FOR ACCESSORIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. GLOBAL ACCESSORIES PATIENT BLOOD MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. PATIENT BLOOD MANAGEMENT MARKET FOR SYRINGES AND NEEDLES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. PATIENT BLOOD MANAGEMENT MARKET FOR VIALS AND TUBES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. PATIENT BLOOD MANAGEMENT MARKET FOR BLOOD BAGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. PATIENT BLOOD MANAGEMENT MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. PATIENT BLOOD MANAGEMENT MARKET FOR REAGENTS AND KITS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. GLOBAL REAGENTS AND KITS PATIENT BLOOD MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. PATIENT BLOOD MANAGEMENT MARKET FOR BLOOD CULTURE MEDIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. PATIENT BLOOD MANAGEMENT MARKET FOR BLOOD TYPING REAGENTS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. PATIENT BLOOD MANAGEMENT MARKET FOR SLIDE STAINING REAGENTS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. PATIENT BLOOD MANAGEMENT MARKET FOR ASSAY KITS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. PATIENT BLOOD MANAGEMENT MARKET FOR SOFTWARE, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. GLOBAL PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. PATIENT BLOOD MANAGEMENT MARKET FOR WHOLE BLOOD AND RED BLOOD CELLS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. PATIENT BLOOD MANAGEMENT MARKET FOR PLASMA, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. GLOBAL PATIENT BLOOD MANAGEMENT MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. PATIENT BLOOD MANAGEMENT MARKET FOR BLOOD BANKS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. PATIENT BLOOD MANAGEMENT MARKET FOR HOSPITALS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. PATIENT BLOOD MANAGEMENT MARKET FOR DIAGNOSTIC CLINICS AND PATHOLOGY LABS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. PATIENT BLOOD MANAGEMENT MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. NORTH AMERICA PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. NORTH AMERICA INSTRUMENTS PATIENT BLOOD MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. NORTH AMERICA ACCESSORIES PATIENT BLOOD MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. NORTH AMERICA REAGENTS AND KITS PATIENT BLOOD MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. NORTH AMERICA PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. NORTH AMERICA PATIENT BLOOD MANAGEMENT MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. NORTH AMERICA PATIENT BLOOD MANAGEMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. U.S. PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. U.S. PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. U.S. PATIENT BLOOD MANAGEMENT MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. CANADA PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. CANADA PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. CANADA PATIENT BLOOD MANAGEMENT MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. MEXICO PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. MEXICO PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. MEXICO PATIENT BLOOD MANAGEMENT MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. EUROPE PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. EUROPE INSTRUMENTS PATIENT BLOOD MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. EUROPE ACCESSORIES PATIENT BLOOD MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. EUROPE REAGENTS AND KITS PATIENT BLOOD MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. EUROPE PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. EUROPE PATIENT BLOOD MANAGEMENT MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. EUROPE PATIENT BLOOD MANAGEMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. GERMANY PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. GERMANY PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. GERMANY PATIENT BLOOD MANAGEMENT MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. FRANCE PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. FRANCE PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. FRANCE PATIENT BLOOD MANAGEMENT MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. UK PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. UK PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. UK PATIENT BLOOD MANAGEMENT MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. ITALY PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. ITALY PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. ITALY PATIENT BLOOD MANAGEMENT MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. SPAIN PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. SPAIN PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. SPAIN PATIENT BLOOD MANAGEMENT MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. REST OF EUROPE PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. REST OF EUROPE PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. REST OF EUROPE PATIENT BLOOD MANAGEMENT MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. ASIA-PACIFIC PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. ASIA-PACIFIC INSTRUMENTS PATIENT BLOOD MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. ASIA-PACIFIC ACCESSORIES PATIENT BLOOD MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. ASIA-PACIFIC REAGENTS AND KITS PATIENT BLOOD MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. ASIA-PACIFIC PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. ASIA-PACIFIC PATIENT BLOOD MANAGEMENT MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. ASIA-PACIFIC PATIENT BLOOD MANAGEMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. CHINA PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. CHINA PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. CHINA PATIENT BLOOD MANAGEMENT MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. JAPAN PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. JAPAN PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. JAPAN PATIENT BLOOD MANAGEMENT MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. INDIA PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. INDIA PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. INDIA PATIENT BLOOD MANAGEMENT MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. AUSTRALIA PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 88. AUSTRALIA PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 89. AUSTRALIA PATIENT BLOOD MANAGEMENT MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 90. REST OF ASIA-PACIFIC PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 91. REST OF ASIA-PACIFIC PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 92. REST OF ASIA-PACIFIC PATIENT BLOOD MANAGEMENT MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 93. LAMEA PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 94. LAMEA INSTRUMENTS PATIENT BLOOD MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 95. LAMEA ACCESSORIES PATIENT BLOOD MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 96. LAMEA REAGENTS AND KITS PATIENT BLOOD MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 97. LAMEA PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 98. LAMEA PATIENT BLOOD MANAGEMENT MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 99. LAMEA PATIENT BLOOD MANAGEMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 100. BRAZIL PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 101. BRAZIL PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 102. BRAZIL PATIENT BLOOD MANAGEMENT MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 103. SAUDI ARABIA PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 104. SAUDI ARABIA PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 105. SAUDI ARABIA PATIENT BLOOD MANAGEMENT MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 106. SOUTH AFRICA PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 107. SOUTH AFRICA PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 108. SOUTH AFRICA PATIENT BLOOD MANAGEMENT MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 109. REST OF LAMEA PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 110. REST OF LAMEA PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 111. REST OF LAMEA PATIENT BLOOD MANAGEMENT MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 112. ASAHI KASEI CORPORATION: KEY EXECUTIVES
  • TABLE 113. ASAHI KASEI CORPORATION: COMPANY SNAPSHOT
  • TABLE 114. ASAHI KASEI CORPORATION: PRODUCT SEGMENTS
  • TABLE 115. ASAHI KASEI CORPORATION: PRODUCT PORTFOLIO
  • TABLE 116. B. BRAUN SE: KEY EXECUTIVES
  • TABLE 117. B. BRAUN SE: COMPANY SNAPSHOT
  • TABLE 118. B. BRAUN SE: PRODUCT SEGMENTS
  • TABLE 119. B. BRAUN SE: PRODUCT PORTFOLIO
  • TABLE 120. BIOMERIEUX SA: KEY EXECUTIVES
  • TABLE 121. BIOMERIEUX SA: COMPANY SNAPSHOT
  • TABLE 122. BIOMERIEUX SA: PRODUCT SEGMENTS
  • TABLE 123. BIOMERIEUX SA: PRODUCT PORTFOLIO
  • TABLE 124. GRIFOLS, S.A.: KEY EXECUTIVES
  • TABLE 125. GRIFOLS, S.A.: COMPANY SNAPSHOT
  • TABLE 126. GRIFOLS, S.A.: PRODUCT SEGMENTS
  • TABLE 127. GRIFOLS, S.A.: PRODUCT PORTFOLIO
  • TABLE 128. GRIFOLS, S.A.: KEY STRATERGIES
  • TABLE 129. HAEMONETICS CORPORATION: KEY EXECUTIVES
  • TABLE 130. HAEMONETICS CORPORATION: COMPANY SNAPSHOT
  • TABLE 131. HAEMONETICS CORPORATION: PRODUCT SEGMENTS
  • TABLE 132. HAEMONETICS CORPORATION: PRODUCT PORTFOLIO
  • TABLE 133. HAEMONETICS CORPORATION: KEY STRATERGIES
  • TABLE 134. HAIER BIOMEDICAL: KEY EXECUTIVES
  • TABLE 135. HAIER BIOMEDICAL: COMPANY SNAPSHOT
  • TABLE 136. HAIER BIOMEDICAL: PRODUCT SEGMENTS
  • TABLE 137. HAIER BIOMEDICAL: PRODUCT PORTFOLIO
  • TABLE 138. IMMUCOR, INC: KEY EXECUTIVES
  • TABLE 139. IMMUCOR, INC: COMPANY SNAPSHOT
  • TABLE 140. IMMUCOR, INC: PRODUCT SEGMENTS
  • TABLE 141. IMMUCOR, INC: PRODUCT PORTFOLIO
  • TABLE 142. LIVANOVA PLC: KEY EXECUTIVES
  • TABLE 143. LIVANOVA PLC: COMPANY SNAPSHOT
  • TABLE 144. LIVANOVA PLC: PRODUCT SEGMENTS
  • TABLE 145. LIVANOVA PLC: PRODUCT PORTFOLIO
  • TABLE 146. MACOPHARMA: KEY EXECUTIVES
  • TABLE 147. MACOPHARMA: COMPANY SNAPSHOT
  • TABLE 148. MACOPHARMA: PRODUCT SEGMENTS
  • TABLE 149. MACOPHARMA: PRODUCT PORTFOLIO
  • TABLE 150. TERUMO CORPORATION: KEY EXECUTIVES
  • TABLE 151. TERUMO CORPORATION: COMPANY SNAPSHOT
  • TABLE 152. TERUMO CORPORATION: PRODUCT SEGMENTS
  • TABLE 153. TERUMO CORPORATION: PRODUCT PORTFOLIO
  • TABLE 154. TERUMO CORPORATION: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. PATIENT BLOOD MANAGEMENT MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF PATIENT BLOOD MANAGEMENT MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN PATIENT BLOOD MANAGEMENT MARKET (2022-2031)
  • FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. HIGH BARGAINING POWER OF BUYERS
  • FIGURE 06. HIGH THREAT OF SUBSTITUTES
  • FIGURE 07. HIGH THREAT OF NEW ENTRANTS
  • FIGURE 08. HIGH INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALPATIENT BLOOD MANAGEMENT MARKET
  • FIGURE 10. PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF PATIENT BLOOD MANAGEMENT MARKET FOR INSTRUMENTS, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PATIENT BLOOD MANAGEMENT MARKET FOR ACCESSORIES, BY COUNTRY 2021-2031(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PATIENT BLOOD MANAGEMENT MARKET FOR REAGENTS AND KITS, BY COUNTRY 2021-2031(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PATIENT BLOOD MANAGEMENT MARKET FOR SOFTWARE, BY COUNTRY 2021-2031(%)
  • FIGURE 15. PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT, 2021(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PATIENT BLOOD MANAGEMENT MARKET FOR WHOLE BLOOD AND RED BLOOD CELLS, BY COUNTRY 2021-2031(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PATIENT BLOOD MANAGEMENT MARKET FOR PLASMA, BY COUNTRY 2021-2031(%)
  • FIGURE 18. PATIENT BLOOD MANAGEMENT MARKET, BY END USER, 2021(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF PATIENT BLOOD MANAGEMENT MARKET FOR BLOOD BANKS, BY COUNTRY 2021-2031(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PATIENT BLOOD MANAGEMENT MARKET FOR HOSPITALS, BY COUNTRY 2021-2031(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF PATIENT BLOOD MANAGEMENT MARKET FOR DIAGNOSTIC CLINICS AND PATHOLOGY LABS, BY COUNTRY 2021-2031(%)
  • FIGURE 22. PATIENT BLOOD MANAGEMENT MARKET BY REGION, 2021
  • FIGURE 23. U.S. PATIENT BLOOD MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 24. CANADA PATIENT BLOOD MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. MEXICO PATIENT BLOOD MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. GERMANY PATIENT BLOOD MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. FRANCE PATIENT BLOOD MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. UK PATIENT BLOOD MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. ITALY PATIENT BLOOD MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. SPAIN PATIENT BLOOD MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. REST OF EUROPE PATIENT BLOOD MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. CHINA PATIENT BLOOD MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. JAPAN PATIENT BLOOD MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. INDIA PATIENT BLOOD MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. AUSTRALIA PATIENT BLOOD MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. REST OF ASIA-PACIFIC PATIENT BLOOD MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. BRAZIL PATIENT BLOOD MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. SAUDI ARABIA PATIENT BLOOD MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. SOUTH AFRICA PATIENT BLOOD MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. REST OF LAMEA PATIENT BLOOD MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 45. COMPETITIVE DASHBOARD
  • FIGURE 46. COMPETITIVE HEATMAP: PATIENT BLOOD MANAGEMENT MARKET
  • FIGURE 47. TOP PLAYER POSITIONING, 2021
  • FIGURE 48. ASAHI KASEI CORPORATION: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 49. ASAHI KASEI CORPORATION: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 50. ASAHI KASEI CORPORATION: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 51. B. BRAUN SE: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 52. B. BRAUN SE: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 53. B. BRAUN SE: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 54. BIOMERIEUX SA: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 55. BIOMERIEUX SA: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 56. BIOMERIEUX SA: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 57. GRIFOLS, S.A.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 58. GRIFOLS, S.A.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 59. GRIFOLS, S.A.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 60. HAEMONETICS CORPORATION: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 61. HAEMONETICS CORPORATION: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 62. HAEMONETICS CORPORATION: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 63. LIVANOVA PLC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 64. LIVANOVA PLC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 65. LIVANOVA PLC: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 66. TERUMO CORPORATION: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 67. TERUMO CORPORATION: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 68. TERUMO CORPORATION: REVENUE SHARE BY REGION, 2021 (%)